Improving CAR T cell therapy for solid tumors by recognizing cancer signals
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
This study is working on improving CAR T cell therapy for solid tumors, like those found in organs, by creating special T cells that can better recognize and attack cancer cells while protecting healthy ones, making treatment safer and more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10987051 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of CAR T cell therapy for solid tumors, which has been challenging compared to its success in blood cancers. The team is developing innovative CAR T cells that can recognize and respond to multiple cancer signals from different cells within the tumor environment. By integrating information from various tumor components, these engineered T cells aim to selectively target cancer cells while minimizing damage to normal tissues. This approach involves creating a two-step recognition process where T cells first identify a priming antigen before targeting the cancer cells for destruction.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who have not responded to conventional treatments.
Not a fit: Patients with blood cancers or those who do not have solid tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer CAR T cell therapies for patients with solid tumors.
How similar studies have performed: While CAR T cell therapy has shown success in blood cancers, this approach for solid tumors is novel and has not been extensively tested yet.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Lim, Wendell a — University of California, San Francisco
- Study coordinator: Lim, Wendell a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.